In Silico Identification of an Aryl Hydrocarbon Receptor (AHR) Antagonist with Biological Activity In Vitro and In Vivo


Molecular Medicine Program, Boston University School of Medicine, Boston, MA (AJP, EAS, ON)
Department of Environmental Health, Boston University School of Public Health, Boston, MA (AJP, EAS, ON, SN, JJS, DHS)
Department of Chemistry and Chemical Biology, Northeastern University, Boston, MA (MPP, TGH)
Department of Chemistry, Boston University (TDA)
Biology Department, Woods Hole Oceanographic Institution, Woods Hole, MA (MEH, DGF)
Wake Forest Innovations, Wake Forest University, Winston-Salem, N.C. (SEH)
Biomedical Engineering, Boston University, Boston, MA (DK, DB, SV)
Running Title: Identification of an AHR antagonist

Corresponding Author: David H. Sherr, Ph.D., Department of Environmental Health, Boston University School of Public Health, 72 East Concord Street (R-408), Boston, MA 02118, dsherr@bu.edu

Text Pages: 34
# Tables: 1
# Figures: 9
# Supplemental Tables: 1
# Supplemental Figures: 5
# References: 73
Abstract words: 220
Introduction words: 765
Discussion words: 1317

ABBREVIATIONS: AHR, aryl hydrocarbon receptor; AHRE, aryl hydrocarbon receptor response element; AHRR, aryl hydrocarbon receptor repressor; β-NF, beta-naphtholfavone; CC, Consensus Cluster; CYP, cytochrome P450; DMBA, 7,12-Dimethylbenz(a)anthracene; DMSO, dimethyl sulfoxide; dpm, disintegrations per minute; EGF, epidermal growth factor; EGFP, enhanced green fluorescent protein; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HTS, high-throughput screen; i.p., intra peritoneal; IC₅₀, inhibitory concentration 50%; LBD, ligand-binding domain; MTT; 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; PAH, polycyclic aromatic hydrocarbon; PBS, phosphate buffered saline; PDB, Protein data base; PPARγ, peroxisome proliferator-activated receptor gamma; PR, progesterone receptor; RFU, relative florescence units; ROCS, rapid overlay of chemical structures; SR1, StemRegenin 1; TCDD, 2,3,7,8-Tetrachlorodibenzo-p-dioxin; TMF, 6,2',4'-trimethoxyflavone; TNBC, triple-negative breast cancer; UPL, unprogrammed lysate
ABSTRACT

The aryl hydrocarbon receptor (AHR) is critically involved in several physiological processes, including cancer progression and multiple immune phenomena. We, and others, have hypothesized that AHR modulators represent an important new class of targeted therapeutics. Here, ligand shape-based virtual modeling techniques were utilized to identify novel AHR ligands based on previously identified chemotypes. Four structurally unique compounds were identified. One lead compound, CB7993113, was further tested for its ability to block three AHR-dependent biological activities: triple negative breast cancer cell invasion or migration in vitro and AHR ligand-induced bone marrow toxicity in vivo. CB7993113 directly bound both murine and human AHR and inhibited PAH- and TCDD-induced reporter activity by 75% and 90% respectively. A novel homology model, comprehensive agonist and inhibitor titration experiments, and AHR localization studies were consistent with competitive antagonism and blockade of nuclear translocation as the primary mechanism of action. CB7993113 (IC$_{50}$ 3.3 x 10$^{-7}$ M) effectively reduced invasion of human breast cancer cells in 3D cultures and blocked tumor cell migration in 2D cultures without significantly affecting cell viability or proliferation. Finally, CB7993113 effectively inhibited the bone marrow ablative effects of 7,12-dimethylbenz[a]anthracene in vivo, demonstrating drug absorption and tissue distribution leading to pharmacological efficacy. These experiments suggest that AHR antagonists such as CB7993113 may represent a new class of targeted therapeutics for immunomodulation and/or cancer therapy.
INTRODUCTION

The aryl hydrocarbon receptor (AHR) field has undergone a dramatic paradigm shift in the last few years. Historically, the evolutionarily conserved AHR was studied for its ability, upon activation by environmental ligands, to regulate genes encoding a battery of cytochrome P450 enzymes that metabolize at least some of those ligands into metabolic intermediates, some of which are toxic (Hankinson et al., 1991; Nebert et al., 1991). Similarly, studies published over the last 20-30 years demonstrate the role of the AHR in the initiation of environmental chemical-induced cancers, to a large extent through P450-dependent generation of mutagenic intermediates. Consequently, studies on the effects of AHR activation, primarily by anthropogenic ligands, most frequently involved tissue toxicity or the initiation of malignancy.

However, several landmark studies now demonstrate that the AHR plays a critical role in several physiological processes in the absence of environmental chemicals. These papers show that the AHR, presumably activated by as yet unidentified endogenous ligands, plays a critical role in the manifestation or control of tissue inflammation and autoimmunity through enforcement of inflammatory cytokine production by monocytes (Wu et al., 2011) and synoviocytes (Lahoti et al., 2013), the production of inflammatory Th17 and immunosuppressive regulatory T cells (Veldhoen et al., 2008a), and the regulation of apoptosis (Caruso et al., 2004; Caruso et al., 2006). Indeed, the recent demonstration that AHR activation drives production of erythroid cells from pluripotent stem cell precursors (Smith et al., 2013), is required for development of gut-associated T cells (Kiss et al., 2011; Lee et al., 2012), and influences the differentiation of human hematopoietic stem cells (Boitano et al., 2010) suggests a critical role of the AHR in hematopoiesis in general.

Furthermore, several studies now implicate the AHR in cancer progression in the absence of environmental ligands. For example, AHR activated by an endogenous tryptophan-derived metabolite increases human glioblastoma cell survival and migration (Opitz et al., 2011).
The AHR repressor (AHRR) protein acts as tumor suppressor gene in several human cancers (Zudaire et al., 2008). AHR expression and “constitutive” (endogenous ligand-driven) activity in breast cancer cells correlate with tumor aggressiveness (Schlezinger et al., 2006b; Yang et al., 2008) and control expression of genes associated with tumor invasion (Yang et al., 2005). Surveys of cytochrome P450 protein expression identified the AHR gene targets CYP1A1, CYP1A2 and CYP1B1 in most types of primary human tumor samples examined, including solid and hematologic malignancies (Maecker et al., 2003), and found that expression of the AHR target gene CYP2S1 inversely correlates with patient survival (Murray et al., 2010). Finally, ectopic AHR expression in non-malignant human mammary epithelial cells induces an epithelial to mesenchymal transition and a >50% increase in cell growth rates (Brooks and Eltom, 2011). Together, these studies strongly support the hypothesis that the AHR plays an important role in the later, more aggressive stages of cancer, even in the absence of environmental ligands.

Given the involvement of the AHR in blood cell development, multiple immune phenomena, and its postulated role in cancer progression, we, and others, have hypothesized that AHR modulators, either agonists or antagonists, may represent an important new class of targeted therapeutics (Schlezinger et al., 2006a; Zhang et al., 2009). We postulate that AHR antagonists in particular may be important for treatment of AHR$^\text{high}$ triple negative breast cancers (TNBCs), malignancies which are particularly resistant to current chemotherapeutics and non-responsive to hormone receptor-targeted therapeutics.

The identification of novel, potent AHR modulators has been hampered by the limited amount of data on the 3D structure of the AHR protein, and specifically on the structure of its ligand-binding domain (LBD). In its stead, researchers have developed structural homology models based on ligand-binding domains of familial proteins (Motto et al., 2011; Xing et al., 2012). Although recent advancements in AHR-LBD models have improved our understanding of the requirements for AHR binding, the powers of these programs to predict AHR ligands are only beginning to be realized.
Here, we utilized ligand shape-based virtual screening techniques to rapidly screen libraries of over 1 million commercially available small molecule compounds for potential AHR ligands. The focused library identified by this analysis was tested in a high-throughput in vitro bioassay for AHR antagonist activity. Lead compounds chosen from the in vitro screening assays were characterized for their ability to directly bind the AHR and to block AHR nuclear translocation and transcriptional activity. One lead compound, CB7993113, was examined for its likely binding conformation to the AHR PAS-B domain. Finally, CB7993113 was tested for its ability to block three AHR-dependent biological activities, triple negative breast cancer cell invasion and migration in vitro and AHR ligand-induced bone marrow toxicity in vivo.

MATERIALS AND METHODS

Chemical Reagents.

Commercial chemical libraries of test compounds were acquired from ChemBridge Corporation and Enamine Ltd. Dimethyl sulfoxide (DMSO), β–Napthoflavone (β–NF), 7,12-dimethylbenz[a]anthracene (DMBA), TCDD and other chemical reagents were obtained from Sigma-Aldrich unless otherwise indicated. CB7993113 and CH223191 were synthesized as below. All compounds submitted for biological testing were deemed at least >98% pure by HPLC (with UV and mass spectral detection) and 1HNMR:

Chemical synthesis of 2-((2-(5-bromofuran-2-yl)-4-oxo-4H-chromen-3-yl)oxy)acetamide (CB7993113). 1-(2-hydroxyphenyl)ethanone (1.720 g, 14.29 mmol) and 5-bromofuran-2-carbaldehyde (2.5 g, 14.29 mmol) were dissolved in a round bottom flask in 10 mL of ethanol. Then, 1.5 mL of a solution of 17 M NaOH in water was added under vigorous stirring. Precipitate formed under addition of base and a thick paste was formed. The mixture was stirred for 24 hours at room temperature. Ethanol (50 mL) was added with 0.5 mL of 2.5 M NaOH. The mixture was cooled to 15° C and hydrogen peroxide was added (35% in water; 6.25 mL, 71.4 mmol). After 4 hours, dilute sulfuric acid was added to neutralize to pH 7.0 and the reaction was
poured into 250 mL of water and stirred for 2 hours. The solid material was collected by filtration and dried under vacuum to give a yellow solid (1.01 g, 23% yield). \(^1\)H NMR (399 MHz, DMSO-\(d_6\)) \(\delta\) ppm 4.60 (s, 2 H) 6.98 (d, \(J=3.66\) Hz, 1 H) 7.39 (br. s., 1 H) 7.50 (t, \(J=7.33\) Hz, 1 H) 7.67 - 7.78 (m, 3 H) 7.81 (d, \(J=7.33\) Hz, 1 H) 8.08 (d, \(J=8.06\) Hz, 1 H). A mixture of 2-(5-bromofuran-2-yl)-3-hydroxy-4H-chromen-4-one thus obtained (910 mg, 2.96 mmol), 2-bromoacetamide (409 mg, 2.96 mmol), potassium carbonate (1229 mg, 8.89 mmol) and dimethylformamide (30 mL) were stirred for 6 hours at 80° C. The solution was cooled and extracted with ethyl acetate. The combined organic layers were washed with water, dried with sodium sulfate, filtered and concentrated. Toluene was added and evaporated repeatedly until dry crystals of crude product were formed. The resulting material was purified by column chromatography, first eluting impurities with 100% ethyl acetate, followed by 10% methanol in methylene chloride to provide CB7993113 as a yellow solid (900 mg, 83% yield). \(^1\)H NMR (399 MHz, DMSO-\(d_6\)) \(\delta\) ppm 4.60 (s, 2 H) 6.98 (d, \(J=3.66\) Hz, 1 H) 7.39 (br. s., 1 H) 7.50 (t, \(J=7.33\) Hz, 1 H) 7.67 - 7.78 (m, 3 H) 7.81 (d, \(J=7.33\) Hz, 1 H) 8.08 (d, \(J=8.06\) Hz, 1 H). (ESI) found 363.9 [M + H]+.

**Chemical synthesis of (E)-1-Methyl-N-(2-methyl-4-(o-tolyldiazenyl)phenyl)-1H-pyrazole-5-carboxamide (CH223191) (Supplemental Figure S1).** A solution containing 4-amino-2',3-dimethylazobenzene (602 mg, 2.67 mM), 1-methyl-1\(^H\)-pyrazole-5-carboxylic acid (372 mg, 2.95 mmol), N,N-diisopropylethyl amine (1.4 mL, 8.04 mmol) and bromotripyrrolidinophosphonium hexafluorophosphate (1.857 g, 3.98 mmol, 1.5 equiv) in 10 mL 1,2-dichloroethane was heated via microwave irradiation in two equal batches at 120° C for 22 minutes. The reaction mixture was reduced in vacuo, taken up in ethyl acetate (100 mL), and washed using 5% K₂HPO₄ (100 mL), saturated NaHCO₃ (100 mL), and brine (100 mL). The isolated organic phase was dried (Na₂SO₄), filtered and concentrated under reduced pressure to give a dark brown solid. The residue was purified twice by rapidly stirring in the minimal amount of warm CH₂Cl₂ and adding hexanes to precipitate the title compound (681 mg, 76%) as an amorphous tan solid. \(^1\)H NMR (300 MHz, CDCl₃) \(\delta\) ppm 8.21 (d, \(J=8.7\) Hz, 1H), 7.86 (dd, \(J=8.7, 2.1, 1\) H), 7.82 (br s, 1H), 7.64
Cell Culture.

H1G1.1c3 cells were generously provided by M.S. Denison (University of California, Davis, CA, USA) and maintained as previously described (Nagy et al., 2002). Cultures of H1G1.1c3 cells were maintained in selective medium consisting of DMEM (Mediatech, Manassas, VA) supplemented with 10% bovine growth serum (HyClone, Logan, UT), 2 mM L-glutamine (Mediatech), 5 μg/mL Plasmocin (Invivogen, San Diego, CA) and 968 mg/L G-418 sulfate (American Bioanalytical, Natick, MA) in a 37°C humidified incubator in a 5% CO₂ atmosphere. This murine hepatoma cell line contains a stable EGFP (enhanced green fluorescent protein) reporter construct regulated by AHREs (AHR response elements) derived from the CYP1A1 promoter.

ER−, PR−, HER2− BP1 cells were generously provided by Dr. J. Russo (Fox Chase Cancer Center, Philadelphia). BP1 cells were maintained in phenol red-free DMEM-F/12 medium (Mediatech) containing 5% equine serum (Sigma-Aldrich), 20 ng/mL human recombinant EGF (Life Technologies), 0.5 μg/mL hydrocortisone (Sigma-Aldrich), 2 mM L-glutamine, 100 IU penicillin/100 μg/mL streptomycin (Mediatech), 10 μg/mL insulin (Sigma-Aldrich) and 5 μg/mL Plasmocin. SUM149 cells were graciously provided by Dr. S. Ethier of Wayne State University (Detroit, MI) who isolated them from a primary inflammatory invasive ductal mammary carcinoma. Cells were maintained in Ham’s F-12 Medium (Mediatech) containing 5% fetal bovine serum (Sigma-Aldrich), 0.5 μg/ml hydrocortisone, 2 μM L-glutamine, 100 I.U. penicillin/100 μg/ml streptomycin, 10 μg/ml insulin, and 5 μg/ml plasmocin. Hs578T cell
culture was described previously (Yang et al., 2008). BP1, Hs578T, and SUM149 cells were cultured and assayed at 37°C in a humidified incubator in a 5% CO₂ atmosphere and grown as adherent monolayers at a maximum of 80% confluency.

**Molecular modeling/Predicting AHR ligands.**

Commercial compound libraries were utilized for shape and electrostatics-based comparisons. Databases of 445,418 compounds from ChemBridge Corporation (San Diego, CA) and 731,288 compounds from Enamine Ltd. (Kiev, Ukraine) were utilized for this scaffold-hopping approach.

The structural file containing a representative flavonoid substructure, 4-oxo-2-phenylchroman-3-yl methylcarbamate, was expanded into a 3D conformer database using OMEGA v.2.2.1 (OpenEye Scientific Software, Santa Fe, NM) (Hawkins and Nicholls, 2012), allowing an energy window of 8 kcal/mol above ground state, and an msd cutoff of 0.8 Å per the method described in Hawkins *et al.* (Hawkins et al., 2007). The two lowest energy conformers were selected and used for subsequent studies.

In a similar way, 3D conformer libraries of the Enamine and ChemBridge collections were generated. No limitation in terms of maximum number of conformers was set. In order to speed this computation, fragment libraries of each were pre-generated using the program **makefragmentlib**. The sample flavonoid conformers were compared against the Enamine and ChemBridge conformer databases using Rapid Overlay of Chemical Structures (**ROCS**;OpenEye). The highest scoring overlaps from **ROCS** were then subjected to electrostatic overlap comparison using **EON** (OpenEye). For hit list ranking, the electrostatic Tanimoto combo (ET_combo) score was used. This is the sum of the shape Tanimoto and the Poisson-Boltzmann electrostatic Tanimoto. The EON hit lists thus generated were merged into two separate structure files (Enamine and ChemBridge) using Pipeline Pilot (Accelrys, San Diego, CA) and each were sorted on the basis of the electrostatic Tanimoto combo score.
(ET_combo). An order list was thus generated consisting of the top 98 hits from ChemBridge and top 99 hits from Enamine. A summary of the computed properties of this library is presented in Supplemental Table S1.

**High Throughput AHR Reporter Assay.**

A previously described AHR reporter assay (Nagy et al., 2002) was adapted for high-throughput screening. \(10^5\) H1G1.1c3 cells were added to each well of a 384-well plate in selective medium and incubated at \(37^\circ\) C for 24 hours. Culture medium was replaced with non-selective medium consisting of MEM\(\alpha\) (Life Technologies, Grand Island, NY) supplemented with 10% BGS (HyClone) and 2 mM L-glutamine (Mediatech) prior to application of the test compounds. \(\beta\)-NF was used as a positive control for induction of AHR reporter activity. A \(\beta\)-NF standard curve was generated by applying vehicle (0.1% DMSO) or final concentrations of \(10^{-10}\) - \(10^{-5}\) M \(\beta\)-NF to the cultures, with each concentration applied to 24 wells. To assess potential AHR agonist activity, vehicle or 2 \(\mu\)l of each of the 197 chemicals in DMSO diluted 1:10 in media (\(10^{-9}\) - \(10^{-6}\) M, final concentration) chosen from commercial libraries were applied to triplicate wells. To screen for AHR antagonist activity, cells in 384-well plates were treated with \(\beta\)-NF (\(10^{-7}\) M) and 2 \(\mu\)L vehicle or test compounds at the indicated concentrations. The plates were incubated at \(33^\circ\) C for up to 72 hours. EGFP fluorescence was analyzed at 24, 48 and 72 hours using a fluorometric plate reader (TECAN, SpectroFluor Plus, Männedorf, CH). Percent induction/inhibition of \(\beta\)-NF-induced AHR activity was calculated by subtracting the background fluorescence of untreated cells from all experimental values and dividing the background-adjusted fluorescence in the sample + \(\beta\)-NF wells by the background-adjusted fluorescence in the \(\beta\)-NF alone wells and then multiplying by 100.

Following the final fluorescence reading, the CellTitre-Blue® cell viability assay was used to determine toxicity as per the manufacturer’s instructions (Promega, Madison, WI).
Toxicity was calculated by dividing background-subtracted fluorescent readings of samples by those of untreated cells. Compounds consistently inducing a $\geq 10\%$ increase in cell death, relative to baseline levels (generally 2%-5%), were excluded from further studies.

**Antagonism of TCDD-induced AHR activity.**

H1G1.1c3 cells ($6 \times 10^5$) were added to each well of a 96-well plate in selective medium and incubated at 37° C for 24 hours. Culture medium was replaced with non-selective medium prior to application of the test compounds. Eight culture wells were treated with 0.5% DMSO (vehicle) or $10^{-7}$ - $5 \times 10^{-11}$ M 2,3,7,8-tetrachlorodibenzo(p)dioxin (TCDD) with or without 0.5% DMSO or $5 \times 10^{-5}$ – $10^{-9}$ M CB7993113. Plates were incubated at 33°C for 24 hrs. EGFP fluorescence was analyzed using a Synergy2 multifunction plate reader (Biotek Inc, Winooski, VT). For each plate, specific fluorescence was calculated by subtracting the background fluorescence in untreated wells from the fluorescence in vehicle- or compound-treated wells. Percent induction was calculated by dividing by the specific fluorescence in the CB7993113+ TCDD wells by the specific fluorescence in cultures treated with Vh + TCDD wells for each given TCDD concentration and multiplied by 100. This experiment was repeated 6 times.

**Efficacy and Potency Analyses**

To determine IC$_{50}$ values, $5 \times 10^4$ H1G1.1c3 cells were added to each well of a 96-well plate and cultured as above. For each experiment, a TCDD standard curve (to normalize fluorescence readings between experiments) was prepared by applying TCDD ($10^{-10}$ - $10^{-6}$ M) or vehicle (DMSO, 0.5%), with each concentration applied to 6 wells. H1G1.1c3 cells were treated with vehicle (DMSO) or titered doses of CB7993113 or CH223191 ($10^{-9}$-$10^{-5}$ M) immediately following addition of vehicle (to assay potential agonist activity), $10^{-7}$ M 7,12-dimethylbenz[a]anthracene or $10^{-7}$ M β-NF (to assay antagonist activity) (6 wells/condition). Plates were incubated at 33° C for 24 hours and EGFP fluorescence was analyzed using a
Synergy 2 plate reader. Percent AHR induction was calculated as described above. Following the final fluorescence reading, the MTT cell viability assay was used to determine toxicity (Sigma-Aldrich, St. Louis, MO). Briefly, after 48 hours incubation, 10 μL MTT (5 mg/mL) was added to each well and incubated at 37°C for 4 hours. Formazan crystals were solubilized by the addition of 100 μL/well DMSO and incubation at 37°C for 2 hours. Absorbance at 570 nm was quantified using a Synergy2 plate reader. Toxicity was calculated by subtracting the average absorbance in the untreated wells from the average absorbance in the experimental wells.

**Homology Modeling/Theoretical AHR Binding.**

The x-ray structure of HIF-2α PAS-B domain co-crystallized with N-(3-chloro-5-fluorophenyl)-4-nitro-2,1,3-benzoxadiazol-5-amine was chosen as the template for model building (Scheuermann et al., 2009). The structure was downloaded from the Protein Data Bank (PDB) (Berman et al., 2002). The PDB identifier (PDB ID) of the structure is 4GHI. The MODELLER program (Version 9.12) was used to generate a model of the human AHR PAS-B domain. MODELLER (Fiser and Sali, 2003) was used to model the human AHR PAS-B domain. Only non-identical residues and regions around the gaps were optimized. To assure that the binding site would not collapse in the process of model building, CB7993113 was aligned inside the homology model, based on the position of the double ring of the ligand in the template and considering the polarity/hydrophobicity of the environment around it. The ligand-protein complex was then minimized using the CHARMM potential in order to avoid potential steric clashes (Brooks et al., 1983). The computational solvent mapping algorithm FTMap was used to predict the most likely CB7993113-AHR PAS-B domain binding position. This method places small molecular probes of various sizes and shapes on a dense grid around the protein, finds favorable positions using empirical energy functions, clusters the conformations, and ranks
the clusters on the basis of the average energy. All ligands and crystallographic water molecules were removed prior to mapping, and the probes were initially distributed over the entire protein surface (including all cavities) without any assumptions about the binding site. The regions that bind multiple low energy probe clusters (consensus cluster/CC sites), identified the most important ligand binding sites. The hot spots were ranked in terms of the number of overlapping probe clusters contained. The consensus cluster with the highest number of probe clusters was ranked first as CC1 and nearby consensus clusters within a 7 Å were also joined with CC1 to form the predicted ligand binding site.

Only non-identical residues and regions around the gaps were optimized and the predicted ligand-protein complex was then minimized using the CHARMM potential (Brooks et al., 1983) to avoid potential steric clashes. The FTMap algorithm (http://ftmap.bu.edu) (Brenke et al., 2009) was used to predict the AHR PAS-B domain-binding hot spots.

(A model of the human AHR PAS-B domain in complex with CB7993113 is provided in supplementary data file C1D1.pdb. A model of the human AHR PAS-B domain in complex with CB7993113, together with computational solvent mapping (http://ftmap.bu.edu) of the PAS-B domain, is provided in supplementary data file CID.pdb).

In vitro Protein Synthesis and Competitive-Binding Assay.

Murine and human AHR proteins were synthesized from AHR expression constructs (pSportMAHR or pSportAHR2, respectively, gifts of Dr. C. Bradfield, U. of Wisconsin, Madison, WI) (Burbach et al., 1992; Dolwick et al., 1993) using a TnT-Quick Coupled Reticulocyte Lysate System (Promega, Madison, WI). The ability of CB7993113 or CH223191 to compete with [3H]TCDD (35 Ci/mmol; Chemsyn Science Laboratories, Lenexa, KS) for binding to human or mouse AHR was measured by velocity sedimentation on sucrose gradients in a vertical tube rotor as described earlier (Karchner et al., 2006). Briefly, single TnT reactions (50 µl) were diluted 1:1 with MEEDMG buffer and incubated overnight at 4°C with [3H]TCDD (2 nM) ±
DMSO or competitor (10 μM final concentration, dissolved in DMSO). Incubations were applied to 10% - 30% sucrose gradients and analyzed as described (Karchner et al., 2006). Nonspecific binding was determined by reactions containing an empty vector (unprogrammed lysate (UPL)).

**Human AHR-Driven Reporter Assay.**

BP1 cells (2 x 10⁴/well) were plated in 24-well plates and allowed to adhere overnight. Cells were co-transfected with 0.1 μg of the pGudLuc reporter plasmid, 0.1 μg CMVgreen and 0.5 μg of either pcDNA or an AHR repressor (AHRR) expression plasmid using Lipofectamine 2000 (Life Technologies, Grand Island, NY) as we previously described (Yang et al., 2008). Cultures were incubated for 3 hours and then dosed with vehicle (DMSO, 0.1%), CH223191 (0.01-1 μM), or CB7993113 (1-20 μM). After 1 hour, the transfection medium was replaced, the cultures were redosed and then incubated for 24 hours. Cells were harvested in Glo Lysis Buffer (Promega) and luciferase activity was determined with the Bright-Glo Luciferase System as per the manufacturer’s instructions (Promega). Luminescence and fluorescence were determined using a Synergy2 plate reader. To calculate “Fold Change from Naïve” the luminescence value was divided by the fluorescence value for each sample.

**Human PPARγ- and CMV-driven Reporter Assays.**

Cos-7 cells were transiently transfected with vectors containing human PPARG1 (kindly provided by V.K. Chatterjee, U. Cambridge, Cambridge, UK)(Gurnell et al., 2000) and human RXRA (plasmid 8882; Addgene) with PPRE x3-TK-luc (plasmid 1015; Addgene) and CMV-eGFP reporter constructs using Lipofectamine 2000 (Invitrogen, Carlsbad, CA). Transfected cultures were incubated for 3 hrs. The medium was replaced with antibiotic-free DMEM with 5% FBS and the cultures were incubated overnight. Cultures received no treatment (Naïve) or were
treated with Vh (DMSO, 0.1%) or rosiglitazone (1 μM) and Vh, CH223191 (10 μM) or CB7993113 (10 μM) and incubated for 24 hrs. Cells were lysed in Glo Lysis Buffer (Promega, Madison, WI). Lysates were transferred to a 96-well plate to which Bright Glo Reagent (Promega) was added. Luminescence and fluorescence were determined using a Synergy2 plate reader. PPARγ-specific luminescence was normalized to the GFP fluorescence in the same well. For the CMV-driven reporter assay, human mammary tumor cells (BP1) were transfected with CMV-driven, eGFP reporter plasmid (>80% transfection efficiency) and treated with CH223191 or CB7993113 as described above. GFP fluorescence was assayed 24 hours later. Constitutive CMV reporter activity was calculated relative to levels seen in naïve cultures.

**Mouse AHR Immunoblotting.**

H1G1.1c3 cells were plated at 2 x 10^6 cells in T75 flasks and allowed to adhere overnight. Cells were treated with CB7993113 (10 μM), vehicle (DMSO, 0.1%) or left untreated for 1 hour, followed by DMBA (10^{-7} M) treatment for 30 minutes. Nuclear and cytoplasmic cell extracts were prepared using the Nuclear Extract Kit (Active Motif, Carlsbad, CA) as per the manufacturer’s instructions. Protein concentration was quantified using Protein Assay Reagent (Bio-Rad, Hercules, CA). Protein (30 μg) was resolved on 12% SDS-polyacrylamide gels and transferred to 0.2 μm nitrocellulose membranes (Bio-Rad). Membranes were probed with the following primary antibodies: mouse anti-AHR (Pierce, cat #MA1-514, Rockford, IL), rabbit anti-Lamin-A/C (Cell Signaling, cat #2032, Danvers, MA) and mouse anti-α-tubulin (EMD Millipore, cat #CP06, Billerica, MA). Immunoreactive bands were detected using HRP-conjugated secondary antibodies (goat anti-rabbit, Bio-Rad; goat anti-mouse Pierce) and ECL substrate.

**Human CYP1B1 mRNA Expression.**
BP1 cells (3 x 10^6) were plated in T225 flasks and allowed to adhere overnight. Cultures were dosed with CB7950998 (10 μM) or vehicle (DMSO, 0.1%) and incubated for 24 hours. mRNA was extracted using RNeasy® Plus Mini Kit (Qiagen, Valencia, CA). cDNA was prepared from total RNA using the GoScript™ Reverse Transcription System (Promega), with a 1:1 mixture of random and Oligo (dT)₁₅ primers. All RT-qPCR reactions were performed using the GoTaq® RT-qPCR Master Mix System (Promega). Validated primers were purchased from Qiagen Inc. (Valencia, CA): Human CYP1B1 - QT00209496, human RRN18S - QT00199367. RT-qPCR reactions were performed using a 7900HT Fast Real-Time PCR instrument (Applied Biosystems, Carlsbad, CA): Hot-Start activation at 95°C for 2 min, 40 cycles of denaturation (95°C for 15 sec) and annealing/extension (55°C for 60 sec). Relative gene expression was determined using the Pfaffl method (Pfaffl, 2001) using the threshold value for RRN18S for normalization. The Cq value from untreated cultures was used as the reference point.

**Invasion and Migration Assays.**

For Matrigel assays, BP1 cells (3 x 10^6 cells/well) were plated in 6-well plates and allowed to adhere overnight. Cells were pre-treated with vehicle (DMSO), CH223191 (10 μM), CB7993113 (5 μM) or left untreated for 24 hours. Cells were harvested and prepared as a single cell suspension for addition to the Matrigel branching assay. Matrigel basement membrane matrix (Becton-Dickinson, Bedford, MA) was diluted to 6.3 mg/mL. Matrigel solution (200 μl) was added to a 24-well plate and solidified at 37°C for 30-45 minutes to form a base layer. Single-cell suspensions containing 2 x 10^4 pre-treated BP1 cells in 10 μl serum-free media were mixed with 190 μl of Matrigel containing 0.1 % vehicle or 5 μM - 10 μM CB7993113. Vehicle or CB7993113 was also added to the Matrigel top layer and the layer allowed to solidify at 37°C for 30-45 minutes. Complete medium (0.5 mL) containing vehicle (DMSO, 0.1%) or CB7993113 (5 or 10 μM) was added on top of solidified Matrigel and was replaced with fresh dosing solution.
every other day. Colony morphology was captured using a Zeiss Axiovert 200 M microscope. Images were captured using a Nikon Coolpix4300 digital camera.

For “scratch wound” assays (Li et al., 2013), Hs578T or SUM149 cells (500,000 cells/well) were plated in 6-well plates and allowed to grow until 100% confluent. Cultures were scratched with a pipette tip, left untreated, or treated with vehicle, 10 μM CH223191, or 10 μM CB7993113, and allowed to regrow for 48 hours. Cultures were photographed using a Nikon CoolPix 4300 attached to a Zeiss Telaval31 inverted microscope at 0 hours, 24 hours and 48 hours.

**In Vivo Studies.**

Male, 6-8 week old C57BL/6J mice were purchased from The Jackson Laboratory (Bar Harbor, ME). All animal studies were reviewed and approved by the Institutional Animal Care and Use Committee at Boston University. For pharmacokinetic studies, 13 week-old mice (four/group) were treated with 50 mg/kg CB7993113 by oral gavage or intraperitoneal (IP) injection. Serum was collected 4, 8 and 16 hours after treatment and from untreated mice. Serum samples were analyzed by LC/MS/MS for CB7993113 at Apredica, Inc. (Watertown, MA). For DMBA-induced bone marrow toxicity studies, mice (6/group) were injected IP with vehicle (100 μl vegetable oil), CH223191 (50 mg/kg) or CB7993113 (50 mg/kg) 24 hours and 1 hour before dosing with 200 μl sesame oil or 50 mg/kg DMBA by oral gavage. Mice were euthanized 48 hours after DMBA treatment. Liver was snap frozen for mRNA analysis. Bone marrow was flushed from femurs and tibiae and RBCs were removed using ACK lysing buffer (BioWhittaker, Lonza, Allendale, NJ).

For gene expression analyses, mRNA was extracted from liver tissues using the RNeasy® Plus Mini Kit (Qiagen, Valencia, CA) and concentrated, if required, using the RNeasy® MinElute Cleanup Kit (Qiagen). cDNA was prepared and RT-qPCR was carried out,
as described above. Primer sequences for murine Cyp1a1 and murine Gapdh were previously described (Xu and Miller, 2004) and were synthesized by IDT (Coralville, IA). Relative gene expression was determined using the Pfaffl method (Pfaffl, 2001), using the threshold value for Gapdh for normalization. The Cq value from untreated animals was used as the reference point.

For flow cytometry analyses, RBC-depleted bone marrow samples were treated with Fc blocking solution (BD Biosciences, San Jose, CA) and suspended in PBS (Life Technologies) supplemented with 2% FBS (Gemini, West Sacramento, CA) for 15 minutes at 4°C. Samples were subsequently surface stained with a cocktail of IgM-, CD24-, CD43- and B220-specific antibodies, a cocktail of Gr-1-, CD3-, NK1.1-, CD11b- and B220-specific antibodies, or their appropriate isotype-matched antibodies for 30 minutes at 4°C in the above staining buffer. All flow cytometry antibodies were obtained from BD Biosciences (San Jose, CA) or eBiosciences (San Diego, CA). Samples were analyzed on a BD™ LSR II instrument. Post-acquisition analysis was performed using FlowJo analysis software (TreeStar).

Statistical Analysis.

Statistical analyses were performed with GraphPad Prism (La Jolla, CA). Data are presented as means ± SEs where applicable. One-tailed Student’s T-tests and one-way ANOVAs with Dunnett, Tukey-Kramer or Newman–Keuls post-hoc were used to determine significance.

RESULTS

Virtual Screening and Generation of Focused Libraries.

Development of modulators that can alter AHR function is of growing importance given the established role that the AHR plays in mediating toxic effects of environmental chemicals and the emerging role of the AHR in inflammatory diseases, autoimmunity, hematopoiesis, and
cancer. To this end, known AHR ligand structures and shape-based modeling were used to predict new AHR ligands and to generate targeted libraries of small molecules with substructures similar to those of known natural and anthropogenic AHR ligands. Noting the prevalence of flavonoid-like molecules in known AHR ligands, a generic substructure, 4-oxo-2-phenylchroman-3-yl methylcarbamate (Supplemental Figure S2) was selected as a basis to search for shape and electrostatic-based similarities in commercial sets of compounds from two vendors, Enamine, Inc. and ChemBridge, Inc.

Databases consisting of 445,418 and 731,288 small molecules from ChemBridge and Enamine, respectively, were scrutinized for 3D conformers similar to the flavonoid substructure using the OMEGA algorithm. The 3D conformer set generated from this analysis was then compared to generic flavonoid substructures by Rapid Overlay of Chemical Structures (ROCS) shape comparison. Subsequently, compounds that ranked highest in structural overlap from the ROCS comparison were subjected to an electrostatic analysis using EON electrostatic comparison and were re-ranked according to their Electrostatic Tanimoto (ET) score. Focused libraries of the top 197 small molecule hits from the Enamine and ChemBridge databases were generated (Supplemental Table S1) and tested for AHR modulating activity in vitro.

In vitro identification of novel AHR antagonists.

A murine reporter-based bioassay (Nagy et al., 2002) was adapted for semi-automated, high-throughput screening of the aforementioned focused library for AHR agonists and antagonists. This assay utilizes the murine hepatoma cell line, H1G1.1c3, which is stably transfected with an AHR-responsive EGFP reporter, to measure AHR transcriptional activity. To assess AHR agonist activity, 1 μM or 5 μM of each experimental compound was added alone to H1G1.1c3 cells. For AHR antagonist screening, each experimental compound was added...
immediately prior to addition of $10^{-7}$ M $\beta$-NF, a well-described AHR agonist. EGFP expression was assayed 24, 48, and 72 hours later.

Of the 197 compounds screened, 31 compounds exhibited agonist activity, as defined by $\geq 25\%$ increase in reporter activity at 1 $\mu$M and 5 $\mu$M and at all three time points when added alone to the reporter assay (data not shown). Four compounds demonstrated significant antagonist activity as defined by $\geq 25\%$ reduction in $\beta$-NF responses at 1 $\mu$M and 5 $\mu$M and at all three time points (Figure 1, arrows). The names and structures of the putative antagonist compounds and, for comparison, that of other previously described AHR antagonists, CH223191 (Kim et al., 2006), SR1 (Boitano et al., 2010), GNF351 (Smith et al., 2011), and 6,2',4'-trimethoxyflavone (Zhao et al., 2010), are provided in Figure 2 and Table 1. Note the relative structural dissimilarity of CB7993113 when compared with most of the other “pure” AHR antagonists.

Several compounds (e.g., $\alpha$-naphthoflavone, galangin) exhibit partial AHR agonism (Dvorak et al., 2008; Santostefano et al., 1993; Zhang et al., 2003). Partial AHR agonists may appear to inhibit the AHR in bioassays since they compete with high efficacy ligands for AHR binding but cannot fully activate the receptor. None of the four putative AHR antagonists discovered in this screen induced AHR-driven reporter activity in the high throughput assay, even at the highest concentration tested (10 $\mu$M) (data not shown and below), indicating that they are not partial agonists.

The potency and efficacy of the four discovered AHR antagonists were compared with CH223191 using the high throughput H1G1.1c3 assay (Figure 3). At maximal concentrations, the four discovered AHR antagonists inhibited between 40$\%$ and 70$\%$ of the $\beta$-NF-induced EGFP signal, with CB7993113 exhibiting the greatest efficacy (Table 1). IC$_{50}$ values ranged from 0.023 $\mu$M to 1.85 $\mu$M (Table 1). None of the compounds were toxic even at the highest dose tested, as defined by $\geq 10\%$ increase in dead cells after 48 hours of exposure. All of the
compounds were within Lipinski’s guidelines for drug-likeness (Lipinski et al., 2001).

Interestingly, the low IC_{50} (i.e., high potency) exhibited by T0515-7358 (0.02 μM) was not
reflected in a significantly higher efficacy (68% inhibition) than the other discovered compounds.
This is not an unusual finding since the potency, in part a function of ligand-receptor affinity,
does not necessarily correlate directly with efficacy, a function of the biological response to the
ligand. This result further highlights differences between AHR antagonists.

Compounds CB7993113 and T0515-hibited the greatest efficacy (maximum percent
inhibition). As anticipated based on calculated lipophilicity (cLogP) values, CB7993113 was
qualitatively observed to be more soluble in PBS than the other compounds and therefore was
prioritized for further study.

In a separate series of experiments, head-to-head comparisons were made between
CH223191 and lead compound CB7993113, using a prototypic, toxic AHR ligand, 7,12-
dimethylbenzanthracene (DMBA) (Teague et al., 2010a), which also was used in in vivo bone
marrow toxicity assays (see below). CB7993113 was slightly less potent than CH223191 as
measured by reduction of DMBA-induced AHR reporter activity in H1G1.1C3 cells (IC_{50}s 2.1 μM
vs. 0.7 μM, respectively, Figure 4A). However, CB7993113 was more effective than CH223191
at reducing DMBA-induced reporter activity under these conditions (46% vs. 28% respectively).
Again, neither CB7993113 nor CH223191 acted as a partial agonist at doses ranging from 1 nM
to 10 μM (Figure 4B) and neither compound exhibited cytotoxicity as determined in an MTT
assay (Figure 4C). Furthermore, neither compound affected reporter activity mediated by an
unrelated nuclear receptor, PPARγ, or reporter activity driven by a constitutive CMV promoter
(Supplemental Figure 3). Collectively, these data indicate that at least one predicted new
compound, CB7993113, specifically antagonizes murine AHR transcriptional activity, does not
exhibit partial AHR agonist activity, and is not cytotoxic, even at relatively high concentrations.
To begin to assess if CB7993113 is likely to be a competitive or allosteric inhibitor, titered concentrations of β-NF (10^{-8} – 10^{-5} M) or TCDD (10^{-13} – 10^{-9} M) and CB7993113 (10^{-7} – 10^{-5} M) were added to H1G1.1c3 cells and the percent induction of TCDD-induced, AHR-driven reporter activity assayed 24 hours later. If CB7993113 is an allosteric inhibitor, then little or no change in the potency (EC₅₀) of an AHR agonist should be seen after addition of titered concentrations of the inhibitor. In contrast, if CB7993113 is a competitive inhibitor, then agonist EC₅₀ should increase as increasing concentrations of inhibitor are added. Indeed, the β-NF and TCDD titration curves shifted to the right (increasing EC₅₀) as the concentration of CB7993113 was increased (Supplemental Figure 4). These data are consistent with competitive inhibition.

A competitive AHR antagonist would be expected to bind directly to the AHR and, at a minimum, block agonist-induced nuclear translocation. Therefore, the capacity of CB7993113 to directly bind to in vitro translated murine AHR protein was determined in a [³H]TCDD competitive binding assay. CH223191 was included as a positive control. As predicted from the calculated IC₅₀s (Figures 3 and 4, Table 1), 10 μM CB7993113 and CH223191 were comparable in their ability to block [³H]TCDD-AHR binding (Figure 5A).

Several AHR ligands, including at least one AHR competitive antagonist (Boitano et al., 2010), exhibit species-specific AHR binding characteristics. Therefore, the ability of CB7993113 to bind human AHR also was assessed using in vitro translated human AHR. The ability of CB7993113 to inhibit the binding of [³H]TCDD to human AHR was similar to that seen with murine AHR, whereas CH223191 was slightly more effective as an inhibitor of [³H]TCDD binding to human AHR as compared to mouse AHR (Figure 5B).

As would be expected from a competitive antagonist, 10 μM CB7993113 completely prevented DMBA-induced AHR nuclear translocation (Figure 5C). Partial inhibition of AHR nuclear translocation was seen in two experiments with as little as 1 μM of CB7993113 (data not shown). Consistent with our findings with the AHR-driven reporter assay, 10 μM CB7993113
alone did not induce nuclear translocation of the AHR protein and thus was not acting as a partial AHR agonist (Figure 5C). These data collectively indicate that CB7993113 is likely a competitive AHR antagonist and that it blocks AHR nuclear translocation and, thereby, transcriptional activity.

**Homology Modeling of CB7993113-AHR binding**

To begin to visualize the orientation of this putative competitive inhibitor in the binding pocket of the human AHR PAS-B domain, the x-ray structure of the HIF-2α PAS-B domain, co-crystallized with the small antagonist, N-(3-chloro-5-fluorophenyl)-4-nitro-2,1,3-benzoxadiazol-5-amine (4GH1) (Scheuermann et al., 2013), was selected as the template for model building. The recent crystal structure of the mouse PAS1 (PAS-A) domain (PDB ID 4M4X) (Wu et al., 2013) indicates that the human AHR PAS-B domain begins after residue Q273, and hence AHR residues 287-390 were aligned with HIF-2α residues 244-348 (Supplemental Figure 5). The two sequences have 27% identity and 50% similarity in this range. Although this level of sequence identity is relatively low for homology modeling, the identical residues distribute almost equidistantly along the domain with only 2% (3 amino acids) gap. This type of distribution makes it very likely that the backbones of the two proteins are very similar. Indeed, structures are available for a number of PAS domains with similar level of sequence identity and good 3D overlap.

The MODELLER mapping results were used in two different ways to approximate CB7993113 docking. First, a box with 4-Å padding was created around the predicted binding site. The docking was carried out restricting consideration to this box and using the standard settings of AutoDock Vina 1.1.0 (Trott and Olson, 2010). The 10 lowest energy binding poses were retained for each ligand. Second, for the selection of the most likely pose, the AutoDock Vina energy score, and the atom densities calculated from the mapping results were included in
the calculus. Probe density was defined at each point binding site as the total number of probe atoms within a 1.25 Å radius. We considered each retained ligand pose and summed the atomic densities for all heavy atoms, resulting in a measure of overlap between the pose and the probe density. The poses with low energy scores were ranked on the basis of this overlap measure, and the pose with the best overlap was selected (Kozakov et al., 2011).

Figure 6A shows the template, the PAS-B domain of HIF-2α, with the bound antagonist. The backbone of the homology model of the human AHR is very similar (Figure 6B). There is no template for the AHR loop 371-376 and thus it was constructed by MODELLER. (Note that this loop is far from the binding site and its exact structure is not important for this model). Figure 6B also shows the probe clusters, obtained by the mapping program FTMap, and indicating the energetically most important regions of the binding site. We note that the sequence differences between HIF-2α and AHR results in a larger binding cavity and greater hydrophobicity of the AHR. Consequently, the site can accommodate CB7993113 in a number of conformations and the 10 lowest energy docked poses of CB7993113 show substantial variation. Figure 6C shows one of the lowest energy structures (pose 2 from AutoDock Vina) that also overlaps well with the binding hot spots. The hydrophobic part of the chromen-3 moiety of the ligand is surrounded by the side chains of F295, M340, and A367, whereas H291 and Q383 donate hydrogen bonds to the more polar regions of CB7993113. For better visibility, Figure 6D shows only a few of the side chains that are within 5Å of the ligand. Interestingly, the differences in the amino acids shown in the AHR yield less bulky side chains, and thus increase the size of the ligand-binding cavity relative to HIF-2α.

CB7993113-mediated inhibition of AHR-dependent biological responses

AHR expression and activation in the absence of environmental ligands is associated with several human cancers including breast cancer (Brooks and Eltom, 2011; Opitz et al., 2011; Schlezinger et al., 2006a). It is presumed that this basal activity is mediated by
endogenous AHR ligands. Therefore, it was predicted that CB7993113, like AHR repressor protein (Yang et al., 2008), would lower baseline levels of AHR-driven reporter activity and endogenous target gene expression in human breast cancer cells. Malignant triple-negative BP1 cells were used for these studies since we had previously established relatively high baseline levels of AHR (reporter) activity and AHR-dependent enforcement of high CYP1B1 levels in this invasive cell line (Yang et al., 2008). BP1 cells were transiently transfected with the pGudLuc AHR-driven reporter plasmid. As previously reported (Yang et al., 2008), co-transfection with a plasmid carrying the AHR repressor gene (Ahrr) significantly reduced baseline pGudLuc reporter activity (Figure 7A). Similarly, treatment of pGudLuc-transfected cells with CB7993113 significantly decreased baseline AHR activity at concentrations as low as 5 µM (Figure 7A). CB7993113 also tended to decrease endogenous CYP1B1 levels in this short-term experiment, although statistical significance was only reached at a concentration of 20 µM (Figure 7B).

Our laboratory (Schlezinger et al., 2006a; Trombino et al., 2000) and others (Brooks and Eltom, 2011; Opitz et al., 2011) have postulated that AHR hyper-expression and activity facilitate malignant transformation. It would then be predicted that AHR antagonists would reverse at least some component of the malignant phenotype. The growth of immortalized cells in irregular, branching colonies in Matrigel is widely seen as a marker for invasiveness (Hughes et al., 2008). Indeed, we have demonstrated that inhibition of AHR activity with AHRR or AHR knockdown with AHR-specific siRNA blocks the formation of branching colonies in human breast cancer cell lines (S. Narasimhan et al., manuscript in preparation). Therefore, the ability of CB7993113 to alter the morphology of BP1 cell colonies in Matrigel was assessed. Untreated or vehicle-treated BP1 cell colonies exhibited the branched, irregular morphology typical of invasive cells as early as day 3 of culture (Figure 7C). However, treatment with either 10 µM CH223191 or 5 µM CB7993113 clearly reduced the size of the colonies and their degree of
branching. Higher magnification images revealed that CB7993113 tended to decrease formation of invasive cell processes (Figure 6D).

It is possible that the morphologic changes seen in the presence of CB7993113 are, in part, a function of altered cell growth or toxicity. However, $^3$H-thymidine incorporation experiments in 2D BP1 cultures failed to demonstrate a significant change in cell growth or viability (>5 experiments, data not shown). Furthermore, the number of viable cells recovered from 7-10 day old 3D Matrigel cultures, as determined by trypan blue exclusion and visual inspection or by propidium iodide exclusion and flow cytometry, was not affected by CB7993113 treatment (3 experiments, data not shown). Therefore, the changes in morphology observed with CB7993113 were not due to decreased cell growth or increased toxicity.

To assess whether CB7993113 inhibits another marker of tumor invasiveness, i.e., migration across a "scratch wound", and to extend studies to two other cell lines, confluent cultures of AHR$_{\text{high}}$ (Yang et al., 2008) Hs578T (triple negative), and SUM149 (inflammatory breast cancer-derived) cells were "wounded" in a scratch assay (Li et al., 2013), treated with vehicle (DMSO), 10 $\mu$M CH223191, or 10 $\mu$M CB7993113, and photographed 24 and 48 hours later. Naïve or vehicle-treated Hs578T and SUM149 cultures closed the scratch wound completely by approximately 56 and 72 hours respectively (not shown). While vehicle had no effect on the rate of wound closure, treatment with either CH223191 or CB7993113 consistently inhibited wound closer with both cell lines at 24 and 48 hours (Figure 8).

Results in both the Matrigel and scratch wound assay are consistent with a role for the AHR in breast cancer cell invasiveness and suggest that the use of AHR antagonists to pharmacologically alter constitutive AHR activity in and potentially invasion of cancer cells.

In vivo efficacy of the AHR antagonist CB7993113.

Drugs to be used as therapeutics must exhibit several properties in vivo including sufficient solubility, absorption, stability, and accumulation in target organs at biologically
relevant concentrations. While *in silico* computation predicted that CB7993113 would satisfy these criteria, *in vivo* studies were required to confirm this prediction. In the absence of an animal model system that faithfully and consistently recapitulates breast cancer cell invasion in humans, we chose to evaluate CB7993113 *in vivo* efficacy using surrogate endpoints of bioactivity, i.e., the ability to block acute AHR-mediated acute DMBA-induced *CYP1A1* induction in liver and AHR-regulated bone marrow toxicity (N’Jai et al., 2011; Teague et al., 2010a).

In pharmacokinetics experiments, 50 mg/kg CB7993113 was readily absorbed *in vivo* following either IP or oral administration. Thus, $823 \pm 263$ nM and $395 \pm 162$ nM CB7993113 were detected in sera 1 hour after IP injection or oral gavage respectively. The compound exhibited a serum half-life of 4.0 hours (data not shown). Therefore, a dose of 50 mg/kg was used for further *in vivo* studies.

As expected from *in vitro* studies, IP injection of 50 mg/kg CB7993113 did not induce *CYP1A1* mRNA expression in liver as assessed by RT-qPCR (Figure 9A), indicating that this compound, or its metabolites, are not partial AHR agonists *in vivo*. In contrast, an equal concentration of DMBA induced a significant, 200-400 fold increase in *CYP1A1* at this 48 hour time point. DMBA-induced *CYP1A1* induction was inhibited by both CH223191 and CB7993113, although inhibition of DMBA-induced *CYP1A1* expression with CH223191 was less consistent than with CB7993113.

In previous studies, we and others demonstrated that DMBA exposure induces a dramatic loss of bone marrow pro- and pre-B cells and other hematopoietic cell types, likely through induction of apoptosis (Mann et al., 1999; N’Jai A et al., 2011; Teague et al., 2010b). To determine if CB7993113 could reach sufficient concentrations *in situ* to block this AHR-dependent bone marrow toxicity, C57Bl/6 mice were treated with vehicle, 50 mg/kg CB7993113 or, as a positive control, 50 mg/kg CH223191, by IP injection 24 hours and 1 hour before oral gavage with 50 mg/kg DMBA. Mice were euthanized 48 hours later, bone marrow cells were collected, and hematopoietic cells were phenotyped by flow cytometry. As expected from *in vitro*
studies in which CB7993113 failed to exhibit toxicity, it also failed to affect the number of bone marrow cells recovered 48 hours after IP injection (Figure 9B). In contrast, a significant reduction in the total number of bone marrow cells was observed after DMBA treatment. This acute bone marrow cell ablation was inhibited by treatment with either CB7993113 or CH223191 (Figure 9B).

Phenotypes of bone marrow subpopulations were analyzed to determine which hematopoietic cell subsets were affected and to determine if CB7993113 could protect all subsets from DMBA-induced toxicity. No significant changes were seen in the resident bone marrow T cell (CD3\(^+\)) or natural killer cell (NK1.1\(^+\)) populations following treatment with DMBA, CH223191, CB7993113, or combinations of DMBA with either antagonist (data not shown). In contrast, DMBA treatment significantly reduced the number of pre/pro-B cells (IgM\(^-/\)B220\(^+/\)CD43\(^+\)/HSA\(^-\)), pro-B cells (IgM\(^-/\)B220\(^+/\)CD43\(^+\)/HSA\(^+\)) (Hardy and Hayakawa, 2001), and neutrophils (CD11b\(^hi\)/GR-1\(^hi\)) (Sukhumavasi et al., 2007) (Figure 9C, 9D, 9E). Notably, pretreatment of mice with either antagonist significantly inhibited DMBA-induced toxicity in all three cell populations. These data confirm the ability of a prototypic AHR ligand to adversely affect bone marrow cells destined to contribute to the adaptive immune response, i.e., pre/pro- and pro-B cells, and to the innate immune response, i.e., neutrophils. Importantly, CB7993113 prevented a significant DMBA-induced loss of these three bone marrow cell subsets. These data demonstrate the achievement of physiologically relevant doses of CB7993113 in vivo, and suggest that this non-toxic antagonist could be used to block AHR activity either induced acutely by environmental ligands or chronically during a variety of pathological conditions.

DISCUSSION

The AHR has been recognized for many years as a key regulator of environmental chemical toxicity and carcinogenicity. Indeed, it mediates the biological effects of some of the most potent toxicants known, including TCDD. Of equal concern, from an environmental point of
view, is the ability of the AHR to bind and respond to a variety of structurally disparate chemicals including planar polychlorinated biphenyls, dioxins, polycyclic aromatic hydrocarbons, plant-derived flavonoids and tryptophan-derived metabolites. While this receptor’s promiscuity and the resulting pathological consequences are reason enough to study AHR signaling pathways, in the end, the AHR’s role in regulating normal and pathological biological activities in the absence of environmental ligands may prove to be the more compelling story. In this vein, the AHR promotes the production of IL-17-secreting T cells critical to inflammation-based diseases and some forms of autoimmunity (Quintana et al., 2012), and affects production of regulatory T cells that oppose inflammatory and autoimmune responses (Apetoh et al., 2010; Gandhi et al., 2010). AHR signaling also plays a key role in development of gut-associated leukocytes which mediate both the innate and adaptive immune responses required to prevent microbial infiltration and the resulting inflammatory colitis (Kiss et al., 2011; Li et al., 2011). In various model systems, the AHR also contributes to hematopoietic stem cell development (Boitano et al., 2010; Casado et al., 2010; Smith et al., 2013). Consequently, the ability to regulate AHR activity may be important for treatment of hematologic diseases. Accordingly, studies have shown that AHR modulation attenuates disease in models of multiple sclerosis and Type I diabetes (Kerkvliet et al., 2009; Quintana et al., 2008). Perhaps most strikingly, AHR modulators have a promising application in stem cell biology as demonstrated by the expansion of human CD34+ progenitor cells from cord blood by culture with the purine-derived AHR antagonist SR1 (Boitano et al., 2010) and the development of bipotential hematopoietic stem cells, megakaryocytes, and erythroid cells from AHR-activated, induced pluripotent stem cells (Smith et al., 2013).

Here, we present a combined in silico and high-throughput in vitro screening platform for the identification of AHR modulators, both agonists and antagonists. Several bioflavonoids, among other phytochemicals, have been identified as AHR ligands. The activity of most of these previously identified compounds ranges from weakly agonistic to weakly antagonistic (Lu et al.,
However, select compounds induce significant AHR-dependent biologic effects, including several flavones such as β-NF, used here as a prototypic AHR agonist. Therefore, we chose a generic substituted flavone backbone as our pharmacophore upon which to perform shape and electrostatic comparisons. In a novel approach to generating a template molecule that could be used to screen over a million small molecules in silico, the flavone-based model pharmacophore was expanded into a 3D conformer database and the molecular shapes were compared to a similar database containing conformers of 1,176,756 commercially available, drug-like molecules. A focused library of 197 compounds was selected based on 3D electrostatic similarities.

The validity of this approach was confirmed by a relatively high “hit” rate. Of the 197 compounds assayed in the bioassay, 31 consistently induced AHR reporter activity with 27 of those exhibiting an EC$_{50}$ of $<$10 μM. Four compounds exhibited AHR antagonist activity, all with IC$_{50}$s $<$5 μM. This represents a hit rate for likely AHR ligands of 17.8%. Cell-free AHR binding studies performed on one antagonist (CB7993113, Figure 5) and one agonist (data not shown) confirmed that each molecule was in fact an AHR ligand. Since both AHR agonists and antagonists may be useful in various therapeutic settings, this new approach to rapidly screening large libraries in silico for AHR ligands has great utility.

Our AHR ligand screen identified a disproportionate number of agonists. This result is consistent with the literature in which identification of AHR agonists is far more common than the identification of pure antagonists, i.e. competitive AHR antagonists that do not exhibit partial agonism at higher doses. To date, relatively few “pure” AHR antagonists have been discovered. These include CH223191 (Kim et al., 2006), 6,2',4'-trimethoxyflavone (TMF) (Murray et al., 2009), SR1 (Boitano et al., 2010), and GNF351 (Smith et al., 2011). Identification of additional AHR antagonists, such as CB7993113, is important because each antagonist appears to exhibit unique properties in terms of affinity for AHRs from different species, “ligand selectivity”, or
ability to block AHR response element-dependent signaling (Smith et al., 2011). For example, SR1 is a potent antagonist of the human AHR but has little or no effect on ligand binding to murine AHR. CH223191 exhibits ligand-selective inhibition, e.g., a propensity to block halogenated hydrocarbon-induced but not flavone-induced AHR activation (Zhao et al., 2010). In contrast, CB7993113 appears to be a more generally applicable AHR antagonist in that it inhibits both human and murine AHR, blocks DMBA-, TCDD-, flavone (β-NF)- and tryptophan metabolite (e.g., FICZ) (data not shown)-induced AHR activity and reduces baseline AHR activity (e.g., baseline pGudLuc activity). It shows no agonist activity either in vitro at doses at least as high as 20 μM or in vivo at doses at least up to 50 mg/kg. Given the number and diversity of possible therapeutic applications for AHR antagonists, including but likely not limited to human hematopoietic stem cell expansion (Boitano et al., 2010), T cell expansion (Carlin et al., 2013), inhibition of inflammatory Th17 development (Veldhoen et al., 2008b), reduction in regulatory T cell development (Apetoh et al., 2010), expansion of erythroid and megakaryocyte lineage cells (Smith et al., 2013), and inhibition of breast cancer cell invasion (Figures 7 and 8), identification of new, non-toxic AHR antagonists is of considerable import. Furthermore, expanding the database of AHR antagonists, which tend to be dissimilar in structure, will facilitate the definition of critical structural characteristics that confer the ability to inhibit, as opposed to induce AHR activity. Again, this knowledge is critical to the rationale design of more potent, non-toxic, pure AHR antagonists for therapeutic use.

Paramount to the identification of a novel antagonist is the confirmation of its drug-likeness and lack of toxicity. In our in vitro screen, compounds exhibiting any level of toxicity in murine H1G1 hepatoma cells were discarded. CB7993113 exhibited no toxicity when added at concentrations at least up to 20 μM to several human cells including HepG2 hepatoma cells, BP1, D3, Hs578T or MDA-MB-231 breast cancer cells, and primary human induced pluripotent stem cells (data not shown). Furthermore, CB7993113 is predicted to conform to Lipinski’s rules.
and thereby is expected to demonstrate oral bioavailability. Pharmacokinetics studies demonstrating significant serum bioavailability after either oral or IP administration were consistent with this conclusion. Most importantly, CB7993113 effectively blocked acute, 50 mg/kg DMBA-induced hepatic CYP1A1 induction and bone marrow toxicity in vivo, demonstrating not only sufficient drug absorption, but adequate tissue distribution and persistence for inhibiting a strong AHR-dependent (Mann et al., 1999; N’Jai A et al., 2011) biological signal.

Finally, pure AHR antagonists like CB7993113 may be useful as cancer therapeutics. Earlier studies implicated the AHR in the control of important cell functions dysregulated during malignant transformation including cell growth (Barhoover et al., 2010) and cell migration (Dietrich and Kaina, 2010). A more recent, high profile study demonstrated that AHR, constitutively activated by an endogenous ligand, drives human glioblastoma invasion (Opitz et al., 2011). Similarly, accumulating evidence suggests that hyper-expressed, “constitutively active” AHR plays a role in the malignant transformation of breast epithelial cells (Brooks and Eltom, 2011; Goode et al., 2013; Hall et al., 2009), the expression of epithelial to mesenchymal transition markers (Schlezinger et al., 2006a; Shin et al., 2006) and, most recently, in breast cancer stem cell homeostasis (Dubrovskaya et al., 2012; Zhao et al., 2012). As shown here, CB7993113 significantly reduces the invasive phenotype of ER-/PR-/HER2- breast cancer cells in vitro (Figures 7 and 8). Although further in vivo experiments are required, these experiments collectively suggest that this, or similar AHR antagonists may represent new targeted therapeutics for some kinds of cancers, including triple negative breast cancers.
MOL #93369

ACKNOWLEDGEMENTS

The authors would like to acknowledge the outstanding technical contributions of Jessalyn Ubellacker and Faye Andrews. MPP acknowledges a free academic license to the OpenEye Suite of Software.

AUTHORSHIP CONTRIBUTIONS:

Participated in research design: Parks, Sherr, Schlezinger, Pollastri, Hahn, Haigh, Vajda, Kozakov, Beglov

Conducted experiments: Parks, Stanford, Novikov, Franks, Hahn, Narasimhan, Kozakov, Beglov, Schlezinger

Contributed new reagents: Ashton, Hopper, Pollastri

Performed data analysis: Parks, Sherr, Schlezinger, Pollastri, Hahn, Vajda, Kozakov, Beglov

Contributed to writing of the manuscript: Parks, Pollastri, Hahn, Kozakov, Beglov, Vajda, Schlezinger, Sherr
REFERENCES


Mann KK, Matulka RA, Hahn ME, Trombino AF, Lawrence BP, Kerkvliet NI and Sherr DH (1999) The role of polycyclic aromatic hydrocarbon metabolism in
MOL #93369


FOOTNOTES:

This work was supported by the National Institute of Environmental Health Sciences [R01ES11624, P42ES007381, R01ES006272]; the National Institute of General Medical Sciences [RO1GM064700]; the Art beCAUSE Breast Cancer Foundation; The Mary Kay Foundation, and a Boston University Ignition Award.

Jennifer J. Schlezinger and David H. Sherr contributed equally to this manuscript.
FIGURE LEGENDS

Figure 1. An *in vitro* AHR bioassay identifies novel AHR antagonists.

H1G1.1c3 cells were left untreated or treated in triplicate wells with vehicle (0.1% DMSO), 1 μM or 5 μM of 197 compounds from the ChemBridge and Enamine focused libraries immediately prior to addition of 10^{-7} M β-NF. Cells were cultured at 33° C for 72 hours. EGFP fluorescence was analyzed at 24, 48 and 72 hours. Data are presented as the average of 3 wells, and are calculated as the percent induction with 100% set at levels seen with 10^{-7} M β-NF alone (dashed line). Data points representing AHR antagonist hits, defined as those compounds with an average induction of ≤75% of β-NF treated cells (green dotted line) for all measured endpoints, are indicated with arrows. Data are representative of a single set of HTS experiments.

Figure 2. Structures of antagonist hit compounds.

Structures of antagonist hits are presented along with their chemical identification numbers. The structure of the previously described AHR antagonists CH223191, SR1, GNF351, and trimethoxyflavone are presented for comparison.

Figure 3. Hit compound characterization led to selection of lead compound, CB7993113.

H1G1.1c3 cells were treated with vehicle (0.1% DMSO) or 10^{-9} - 10^{-5} M of AHR antagonists immediately prior to stimulation with 10^{-7} M β-NF. Fluorescence (AHR-dependent reporter activity) was assayed 24, 48, and 72 hours later as in Figure 1. Dose response curves were generated utilizing a three-parameter dose-response curve model in GraphPad Prism with a standard Hill slope of -1. Data are presented as the average of 3 wells and are calculated as the percent induction with 100% set at levels seen with 10^{-7} M β-NF alone.
Figure 4. CB7993113 blocks DMBA-induced AHR-dependent reporter activity.

A) H1G1.1c3 cells were treated with vehicle (0.1% DMSO) or 10^{-9} - 10^{-5} M CB7993113 or CH223191 immediately prior to stimulation with 10^{-7} M DMBA and culture at 33°C. EGFP fluorescence (AHR reporter activity) was analyzed 24 hours later. B) AHR agonist activity was measured by treating H1G1.1c3 cells with vehicle or 10^{-9}-10^{-5} M CB7993113 or CH223191. Cells were cultured at 33°C and EGFP fluorescence was analyzed after 24 hours. Dose response curves were generated utilizing a three-parameter dose-response curve model in GraphPad Prism with a standard Hill slope of -1 (A,B). C) Cellular toxicity after the above treatment was measured by the MTT reduction assay 48 hours after addition of compounds. Data are presented as means ± SE of 3 independent experiments. ANOVA with Dunnett’s post-test, **p<0.01 or ***P<0.001 for CB7993113 as compared to vehicle, ++p<0.01 or +++P<0.001 for CH223191 compared to vehicle.

Figure 5. CB7993113 directly binds murine AHR protein and blocks AHR nuclear translocation.

In vitro-expressed murine AHR (mAHR) (A) or human AHR (hAHR) (B) protein was incubated with 2 nM [3H]TCDD in the presence of vehicle (DMSO), 10 µM CH223191 or 10 µM CB7993113 for 12 hours. Quantification of [3H]TCDD-AHR binding was analyzed by velocity sedimentation on sucrose gradients. Data are representative of 2 independent experiments. C) H1G1.1c3 cells were treated with vehicle (0.1% DMSO) or 10 µM CB7993113 for 1 hour, followed by treatment with 10^{-7} M DMBA for 30 minutes. Cytoplasmic and nuclear extracts were isolated and analyzed for AHR, α-tubulin and lamin A/C content by immunoblotting. Data are representative of 4 independent experiments.

Figure 6. Homology Modeling of CB7993113 binding to human AHR
Homology modeling based on the crystal structure of ligand-bound HIF-2α was employed as described in the text. **A)** Structure of ligand-bound HIF-2α. **B)** Depicted is a proposed model of CB7993113 docking to human AHR, including the probe clusters, obtained by the mapping program FTMap, and indicating the energetically most important regions of the binding site. 

**C)** Shown is the hydrophobic part of the chromen-3 moiety of the ligand which is surrounded by the side chains of F295, M340, and A367. **D)** Shown are a few side chains that are within 5Å of the ligand. Residue numbers in parentheses represent the corresponding residues of HIF-2α (see Supplemental Figure 5).

**Figure 7.** CB7993113 and CH223191 reduce the invasive phenotype of human breast cancer cell colonies in 3D Matrigel assays.

**A)** BP1 cells were co-transfected with AHRE-driven firefly luciferase reporter (pGudluc) and control CMV green (GFP) vectors and incubated for 3 hrs. In some groups, AHRR plasmid was co-transfected as a positive control. Cultures were left untreated or were treated with vehicle (0.1% DMSO) or 1-20 µM CB7993113. Cells were harvested 24 hours later and luciferase activity assayed. Luciferase (AHR-reporter) activity was first normalized to the GFP signal to control for transfection efficiency and then normalized to the luciferase signal obtained from untreated cells. Data are expressed as means ± SE obtained from 3 independent experiments. ***P<0.001 as compared to vehicle groups, ANOVA with Dunnett’s post-test) **B)** BP1 cells were treated with vehicle (DMSO) or 1-20 µM CB7993113 for 24 hours. mRNA was extracted and analyzed by qPCR for CYP1B1 expression normalized to 18sRNA expression. qPCR was performed in duplicate. Data are expressed as means ± SE from 3-5 independent experiments. (*p<0.05, as compared to vehicle groups, ANOVA with Dunnett’s post-test) **C)** BP1 cells were treated with vehicle (0.1% DMSO), 10 µM CH223191, 5 µM CB7993113 or left untreated for 24 hours. Cells were harvested, counted and plated in Matrigel. Representative images from 3
independent experiments were taken on days 3 and 5. D) BP1 cells were treated as in “C” with vehicle or CB7993113 (10 µM). High magnification images were captured on day 5 to illustrate cell morphology. CB7993113-treated cells extracted from matrigels were ~95% viable. No significant differences in the numbers of cells in cultures after extraction from 3D cultures was seen. E) BP1 cells were treated with CB7993113 (10 µM) and incubated for 8-10 hours after which 3H-thymidine was added and cells further incubated for 16-18 hours. The cells were harvested and CPM incorporation was measured. In each experiment data were normalized to 3H-thymidine incorporated in non-transfected cells. Data are presented as mean ± SE of 4 experiments, *p<0.017.

**Figure 8. CB7993113 blocks mammary tumor cell migration in a scratch wound assay.**

Confluent monolayers of Hs578T (triple negative breast cancer) and SUM149 (inflammatory breast cancer) cells, scratched with a pipette tip, were treated with vehicle, 10 µM CH223191, or 10 µM CB7993113, and allowed to regrow for 48 hours. Cultures were photographed 24 and 48 hours after wounding. Images taken at 24 and 48 hours are representative of results obtained in 6 experiments.

**Figure 9. CB7993113 prevents DMBA-induced toxicity in vivo.**

Eight week old C57BL/6J mice (6/group) were treated by i.p. injection with vehicle (vegetable oil), 50 mg/kg CH223191, or 50 mg/kg CB7993113 24 hours and 1 hour before DMBA treatment. Vehicle (sesame oil) or 50 mg/kg DMBA was then administered by oral gavage. Mice were sacrificed 48 hours after DMBA treatment. A) Liver mRNA was extracted and analyzed by qPCR for CYP1A1 expression normalized to GAPDH expression. qPCR was performed in duplicate. Data bars represent the mean values from 6 mice. B) Bone marrow was harvested from the right tibia and femur of each mouse and viable cells were counted by trypan
blue exclusion. Data bars represent the mean values from 6 mice. C,D,E) Bone marrow was harvested and analyzed by flow cytometry. C) Pre/Pro B cells are defined as IgM-/B220+/CD43+/HSA-. D) Pro B cells are defined IgM-/B220+/CD43+/HSA+. E) Neutrophils are defined as CD11bhi/GR-1hi. Data bars represent the mean values from 6 mice. Data were analyzed by ANOVA with Tukey-Kramer post-test (A,B) or Newman-Keuls post-test (C,D,E), *p<0.05, **p<0.01, ***P<0.001 as compared to vehicle, +p<0.05, ++p<0.01 or +++P<0.001 as compared to DMBA treatment.

CID1.pdb Caption: A model of the human AHR PAS-B domain in complex with CB7993113

CID.pdb Caption: A model of the human AHR PAS-B domain in complex with CB7993113 together with computational solvent mapping (http://ftmap.bu.edu) of the PAS-B domain.
# Table 1. AHR antagonist hit compounds

Vendor catalog numbers, chemical names, molecular weights and Log P (partition coefficient) values, are presented. The cLogP values were determined using Pipeline Pilot. Maximum percent Inhibition values were determined from data presented in Figure 3 using 50 μM of the respective compounds and assaying on day 3. IC<sub>50</sub> values were determined from the dose-response curves generated in Figure 3 using GraphPad Prism.

<table>
<thead>
<tr>
<th>Chemical ID</th>
<th>Chemical Name</th>
<th>MW</th>
<th>Log P</th>
<th>Max % Inhibition</th>
<th>IC&lt;sub&gt;50&lt;/sub&gt; (μM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CB7993113</td>
<td>2-[[2-(5-bromo-2-furyl)-4-oxo-4H-chromen-3-yl]oxy]acetamide</td>
<td>364.1</td>
<td>1.03</td>
<td>70.3</td>
<td>0.33</td>
</tr>
<tr>
<td>T0515-7358</td>
<td>2-phenyl-5,6,7,8-tetrahydro-4H-chromene-4-thione</td>
<td>242.3</td>
<td>3.88</td>
<td>67.7</td>
<td>0.02</td>
</tr>
<tr>
<td>T5448133</td>
<td>2-(benzyl)oxy-N-(5-ethyl-1,3,4-thiadiazol-2-yl)benzamide</td>
<td>339.4</td>
<td>3.91</td>
<td>61.6</td>
<td>1.85</td>
</tr>
<tr>
<td>T6047668</td>
<td>2-((4-fluorobenzyl)oxy)-N-(5-isopropyl-1,3,4-thiadiazol-2-yl)benzamide</td>
<td>371.4</td>
<td>4.60</td>
<td>40.3</td>
<td>0.04</td>
</tr>
<tr>
<td>CH223191</td>
<td>(E)-1-Methyl-N-(2-methyl-4-(o-tolyldiazenyl)phenyl)-1H-pyrazole-5-carboxamide</td>
<td>333.4</td>
<td>4.85</td>
<td>69.6</td>
<td>0.24</td>
</tr>
</tbody>
</table>
Figure 2

Chemical structures of various compounds including CB7993113, T05157358, T5448133, T6047668, CH223191, SR1, GNF351, and 6,2',4'-trimethoxyflavone.
Figure 3

% Induction vs. Vh for various molecules and time points:

- CB7993113 [M]
- T5448133 [M]
- T0515-7358 [M]
- T6047668 [M]
- CH223191 [M]
Figure 4

A

B

C

% Induction

% Induction

OD (570 nM)

Concentration [M]

Concentration [M]

Concentration [M]
Figure 5

A

B

C

Cytoplasmic

AhR

α-Tubulin

Nuclear

AhR

Lamin A/C

Vehicle

DMBA

CB7993113

[\text{[^3]H]TCDD (dpm)}]

Fraction

0 1 6 11 16 21 26 31 36

[\text{[^3]H]TCDD (dpm)}]

Fraction

0 1 6 11 16 21 26 31 36

[\text{[^3]H]TCDD (dpm)}]

Fraction

0 1 6 11 16 21 26 31 36
Figure 6
Figure 7

A

AhR Activity (Fold Change from Naïve)

CB7993113 [µM]

AhRR

Vn

1

5

10

20

***

***

***

***

B

CYP1B1 mRNA (Fold Change from Naïve)

CB7993113 [µM]

Vn

1

5

10

20

*

C

Naïve

Vehicle

CH223191 (10 µM)

CB7993113 (5 µM)

Day 3

Day 5

D

Vehicle

CB7993113

Day 5